Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate anatomical responses and visual changes in cases of exudative age-related macular degeneration (AMD) with choroidal vascular hyperpermeability (CVH) that responded poorly to multiple ranibizumab injections and were treated with intravitreal aflibercept.

Design

Retrospective comparative study.

Participants

Twenty-five consecutive patients attending the outpatient clinic of the University of Tokyo Hospital who showed an insufficient response to multiple intravitreal ranibizumab injections and were switched to intravitreal aflibercept injections between March and June 2013. All patients were treated with intravitreal aflibercept in a treat-and-extend regimen and followed up for at least 12 months.

Methods

Presence or absence of CVH was determined by indocyanine green angiography. Changes of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months were compared between the CVH (+) AMD and CVH (−) AMD eyes.

Results

The improvement in logMAR BCVA at 12 months was larger in the CVH (−) AMD eyes than in the CVH (+) AMD eyes (−0.18 vs −0.026; P = 0.0089, t-test). The changes in CRT did not differ significantly between the groups (−122 ± 101 μm in the CVH (−) AMD eyes and −159 ± 118 μm in the CVH (+) AMD eyes; P = 0.44, t-test). The proportion of the eyes without intraretinal or subretinal fluid or hemorrhage was 88 % in the CVH (−) AMD and 67 % in the CVH (+) AMD (P = 0.21, t-test).

Conclusions

Compared with AMD without CVH, AMD with CVH showed poorer visual gain resulting from intravitreal aflibercept treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14:231–42.

    Article  CAS  PubMed  Google Scholar 

  2. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121:26–34.

    Article  CAS  PubMed  Google Scholar 

  3. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070–9.

    Article  CAS  PubMed  Google Scholar 

  4. Lafaut BA, Salati C, Priem H, De Laey JJ. Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patients. Graefeʼs Arch Clin Exp Ophthalmol. 1998;236:513–21.

    Article  CAS  Google Scholar 

  5. Tsujikawa A, Ojima Y, Yamashiro K, Ooto S, Tamura H, Nakagawa S. Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography. Retina. 2010;30:801–9.

    Article  PubMed  Google Scholar 

  6. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.

    Article  CAS  PubMed  Google Scholar 

  7. Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol. 2006;142:601–7.

    Article  PubMed  Google Scholar 

  8. Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012;53:3663–72.

    Article  CAS  PubMed  Google Scholar 

  9. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol. 2013;155:305–13.

    Article  PubMed  Google Scholar 

  10. Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, et al. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156:1192–200.

    Article  CAS  PubMed  Google Scholar 

  11. Miyake M, Tsujikawa A, Yamashiro K, Ooto S, Oishi A, Tamura H, et al. Choroidal neovascularization in eyes with choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55:3223–30.

    Article  PubMed  Google Scholar 

  12. Nomura Y, Takahashi H, Tan X, Obata R, Yanagi Y. Widespread choroidal thickening and abnormal midperipheral fundus autofluorescence characterize exudative age-related macular degeneration with choroidal vascular hyperpermeability. Clin Ophthalmol. 2015;9:297–304.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34:1531–8.

    Article  CAS  PubMed  Google Scholar 

  14. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.

    Article  PubMed  Google Scholar 

  15. Nomura Y, Takahashi H, Tan X, Fujimura S, Obata R, Yanagi Y. Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol. 2014;58:443–7.

    Article  CAS  PubMed  Google Scholar 

  16. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121:188–92.

    Article  PubMed  Google Scholar 

  17. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605–12.

    Article  CAS  PubMed  Google Scholar 

  18. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156:15–22.

    Article  CAS  PubMed  Google Scholar 

  19. Heussen FM, Shao Q, Ouyang Y, Joussen AM, Muller B. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol. 2014;252:909–15.

    Article  CAS  Google Scholar 

  20. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol. 2013;97:1032–5.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

Y. Nomura, None; Y. Yanagi, None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Yoko Nomura & Yasuo Yanagi

Authors
  1. Yoko Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuo Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Yanagi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLSX 11 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nomura, Y., Yanagi, Y. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Jpn J Ophthalmol 59, 261–265 (2015). https://doi.org/10.1007/s10384-015-0387-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-015-0387-z

Keywords

Search

Navigation